 The FDA has extended the review period for Kadmon Holdings Incs NASDAQ: KDMN marketing application seeking approval for belumosudil to treat chronic graft-versus-host disease cGVHD. The goal date for the Priority Review of belumosudil has been extended to August 30, from May 30. 